Corebridge Financial Inc. Trims Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Corebridge Financial Inc. decreased its position in shares of Enliven Therapeutics, Inc. ( NASDAQ:ELVN – Free Report ) by 7.

0% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 17,500 shares of the company’s stock after selling 1,321 shares during the period. Corebridge Financial Inc.



’s holdings in Enliven Therapeutics were worth $394,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new position in shares of Enliven Therapeutics during the 4th quarter worth $97,000.

China Universal Asset Management Co. Ltd. boosted its stake in Enliven Therapeutics by 14.

0% in the 4th quarter. China Universal Asset Management Co. Ltd.

now owns 10,360 shares of the company’s stock worth $233,000 after buying an additional 1,275 shares during the last quarter. Verition Fund Management LLC purchased a new stake in Enliven Therapeutics in the 3rd quarter valued at about $271,000. Intech Investment Management LLC purchased a new stake in Enliven Therapeutics in the 4th quarter valued at about $367,000.

Finally, SG Americas Securities LLC lifted its holdings in shares of Enliven Therapeutics by 66.1% during the 4th quarter. SG Americas Securities LLC now owns 16,629 shares of the company’s stock worth $374,000 after acquiring an additional 6,616 shares during the period.

95.08% of the stock is owned by hedge funds and other institutional investors. Analysts Set New Price Targets Several equities analysts recently commented on the stock.

BTIG Research initiated coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 price target for the company.

HC Wainwright upped their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 21st.

Enliven Therapeutics Trading Up 4.4 % Shares of ELVN stock opened at $16.52 on Thursday.

The company’s fifty day simple moving average is $20.56 and its 200-day simple moving average is $23.41.

The company has a market cap of $809.55 million, a PE ratio of -8.69 and a beta of 1.

03. Enliven Therapeutics, Inc. has a 52 week low of $14.

47 and a 52 week high of $30.03. Enliven Therapeutics ( NASDAQ:ELVN – Get Free Report ) last announced its earnings results on Thursday, March 13th.

The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.

07. The company had revenue of $0.03 million for the quarter.

Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Activity In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $21.44, for a total transaction of $142,940.

48. Following the sale, the chief operating officer now owns 323,310 shares in the company, valued at $6,931,766.40.

This represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link .

Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $21.59, for a total value of $70,167.

50. Following the transaction, the chief financial officer now directly owns 13,000 shares in the company, valued at approximately $280,670. This represents a 20.

00 % decrease in their position. The disclosure for this sale can be found here . Insiders sold 56,751 shares of company stock worth $1,178,263 over the last ninety days.

Corporate insiders own 29.20% of the company’s stock. About Enliven Therapeutics ( Free Report ) Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. Further Reading Five stocks we like better than Enliven Therapeutics What is a Secondary Public Offering? What Investors Need to Know Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore Most Volatile Stocks, What Investors Need to Know Are Tariffs Threatening Disney’s Comeback Story? Should You Invest in Penny Stocks? Is Alphabet a Generational Buying Opportunity at These Levels? Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.

com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. ( NASDAQ:ELVN – Free Report ). Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.

com's FREE daily email newsletter ..